Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00384
|
|||||
Drug Name |
Risperidone
|
|||||
Synonyms |
3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[-4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one; 3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperi-dino]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]-ethyl}-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; Belivon; Consta, Risperdal; KS-1106; R 62 766; R 64 766, Risperdal, Risperidone; R 64,766; R 64766; R-118; R-64,766; R-64-766; R-64766; R64,766; R64766; Risperdal; Risperdal (TN); Risperdal Consta; Risperdal M-Tab; Risperdone; Risperidal; Risperidal M-Tab; Risperidona; Risperidona [Spanish]; Risperidone (JAN/USAN/INN); Risperidone (RIS); Risperidone [USAN:BAN:INN]; Risperidone, placebo; Risperidonum; Risperidonum [Latin]; Risperin; Rispolept; Rispolin; Sequinan
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
Therapeutic Class |
Antipsychotic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C23H27FN4O2
|
|||||
Canonical SMILES |
CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
|
|||||
InChI |
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
|
|||||
InChIKey |
RAPZEAPATHNIPO-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 106266-06-2
|
|||||
Pharmaceutical Properties | Molecular Weight | 410.5 | Topological Polar Surface Area | 61.9 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 4 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 6 | |||
XLogP |
2.7
|
|||||
PubChem CID | ||||||
PubChem SID |
103170825
, 103856459
, 103914673
, 103916252
, 11111724
, 11111725
, 11467057
, 11468177
, 11486814
, 11528727
, 12013967
, 14904216
, 17405630
, 25819945
, 26719830
, 26753640
, 29224142
, 46386613
, 46505850
, 49658633
, 49666400
, 49681677
, 49699257
, 49830253
, 50106974
, 50106975
, 50123965
, 53778180
, 53790689
, 57322595
, 631811
, 7379882
, 7847492
, 7980523
, 80652519
, 81092846
, 8153122
, 85089206
, 85170980
, 85209258
, 85231208
, 85788353
, 89736125
, 92126063
, 92303273
, 92308377
, 92308738
, 92712792
, 93166420
, 93617025
|
|||||
ChEBI ID |
ChEBI:8871
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | P-GP | Transporter Info | Km = 12.4 microM | Baculovirus-infected insect cells-MDR1 | [3] | |
References | ||||||
1 | Risperidone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005 Jul;78(1):43-51. | |||||
3 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.